AstraZeneca(US:AZN) Prnewswire·2025-01-21 10:45Core Viewpoint - A class action securities lawsuit has been filed against AstraZeneca PLC, alleging securities fraud that adversely affected investors between February 23, 2022, and December 17, 2024 [1][2]. Group 1: Lawsuit Details - The complaint alleges that AstraZeneca engaged in insurance fraud in China, leading to heightened legal exposure and the detention of the AstraZeneca China President by law enforcement [2]. - It is claimed that AstraZeneca understated its legal risks, and the revelation of these issues could materially harm its business activities in China [2]. - The defendants' statements regarding AstraZeneca's business, operations, and prospects are alleged to be materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 21, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].